This study was designed to examine the prediction of pretreatment circulating bilirubin and cholesterol for overall survival in 459 advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Circulating total bilirubin, direct bilirubin (DB), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were measured at baseline. The mean age (standard deviation) of all study patients was 58.7 (10.5) years, and 42.9% of them was males. Ever smokers accounted for 27.0% and lung adenocarcinoma for 90.4%. The median follow-up time and survival time were 29.5 and 34.9 months, respectively. Patients with higher DB had a 1.68-fold increased risk of death compared with patients with lower DB (hazard ratio [HR] 5 1.68, 95% confidence interval [CI]: 1.22-2.30, p 5 0.001), while patients with higher TC were at a 63% reduced risk of death compared with patients with lower TC (HR 5 0.37, 95% CI: 0.20-0.67, p 5 0.001). As for HDL-C, patients with higher levels had the risk of death reduced by 46% (HR 5 0.54, 95% CI: 0.29-1.00, p 5 0.049) compared with patients with lower levels. After the Bonferroni correction, only DB and TC were significantly associated with NSCLC survival. Our findings demonstrate for the first time that pretreatment DB was identified as a significant risk factor, yet TC as a protective factor, for overall survival in NSCLC patients with EGFR mutations.
Despite tremendous therapeutic advances gained over the last decade, lung cancer still remains the leading cause of cancerrelated death worldwide. 1 According to the report of American Cancer Society, NSCLC in the US accounts for 85% of all lung cancer cases. 2 Traditionally, platinum-based chemotherapy has been the mainstay of systemic treatment for patients with advanced NSCLC, whereas the improvement is only modest with estimated median overall survival (OS) of 12 months or less. 3 Recent evolution of molecular targeted therapies, especially the emergence of epidermal growth factor receptor (EGFR) inhibitors, has been demonstrated to be feasible and efficacious in elongating OS in NSCLC patients with EGFR mutations. 4, 5 However, several studies have shown that EGFR-TKI treatment can significantly improve progression-free survival (PFS), but not OS, as compared with the conventional first-line chemotherapy. [6] [7] [8] This difference is mainly attributed to the high proportion of patients crossed over to the alternative treatment. 8 Although a metaanalysis indicated a potential effect of EGFR-TKI on improving OS for NSCLC patients with del19 EGFR mutations, 9 it is still urgently needed to seek certain easy-to-obtain biomarkers that can better predict the OS of NSCLC patients with EGFR mutations in light of sparse data from medical literature. Currently, metabolic profiling is increasingly recognized as a useful tool for understanding mechanisms of lung carcinogenesis, and the association between metabolic abnormalities and lung cancer risk has been widely evaluated. [10] [11] [12] [13] In particular, circulating bilirubin and cholesterol are the two key metabolic biomarkers. Bilirubin, a bile pigment, is the major end product of heme degradation and cleared from liver, and has potential properties of anti-inflammation, antioxidation and anticancer. 16 As reported by previous studies, bilirubin was inversely associated with an increased risk of lung cancer. 13, 17, 18 Similarly, dysfunctional metabolism of cholesterol in circulation was also proposed to be related with the development of lung cancer. 19,20. However, the impact of circulating bilirubin and cholesterol on the prognosis of NSCLC, especially in patients with EGFR mutations, thus far remains largely unknown. As an initial step toward unraveling this impact, we enrolled 459 advanced NSCLC patients carrying EGFR mutations with a median follow-up period of 29.5 months, aiming to examine the prediction of pretreatment circulating bilirubin and cholesterol for the OS.
Materials and Methods

Study patients
All patients who received treatment for lung cancer were consecutively enrolled from the Department of Pulmonary at Shanghai Chest Hospital between January 2009 and December 2013. Only NSCLC patients were incorporated in this study, and they were histologically confirmed according to the classification criteria of the World Health Organization. 21 Written informed consent was obtained from each patient and the ethical committee of Shanghai Chest Hospital approved this study.
Eligibility
Patients were included if the following criteria were simultaneously satisfied: (1) tumor node metastasis (TNM) stage: IIIB to IV or inoperable IIIA with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2; (2) EGFR mutation: positive; (3) without clinical treatment before serum collection; (4) with complete follow-up data. In contrast, patients were excluded if they had concomitant diseases (i.e., hepatobiliary or hemolytic disease, diabetes, hyperlipidemia or metabolic syndrome) or received any agents that can alter circulating bilirubin and cholesterol levels (i.e., hormone replacement therapy, reduced glutathione or any other drugs known to affect bilirubin and lipid metabolism), or missing data on pretreatment bilirubin or cholesterol.
Follow-up assessment
Follow-up was performed annually after discharge at the Out-Patient Department of Shanghai Chest hospital or through telephone interview or post mail by trained persons in case of no-show at the scheduled time. The endpoint of this study was OS, which was defined from the date of diagnosis to the date of death or the latest follow-up, whichever came first. Survivors were defined as alive at the time of latest follow-up, whereas nonsurvivors were defined as dead at any time of annual follow-up.
Data collection
At baseline, information on age at diagnosis, gender and smoking history was collected by a structured questionnaire. Meanwhile, clinicopathological data, treatment regimens and follow-up outcomes were abstracted from electronic medical records by trained and experienced doctors.
Clinical measurement
Total bilirubin (TB), direct bilirubin (DB), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and lowdensity lipoprotein cholesterol (LDL-C) levels were measured with fasting blood samples by standard tests before treatment for lung cancer.
Statistical analysis
Continuous data were expressed as mean ( The cumulative overall survival rates were depicted by Kaplan-Meier curves and were compared by Log-rank tests for each dichotomized biomarker by the optimal cutoff point. Stratified analyses were performed separately according to gender, smoking status, TNM stage, histology and EGFR mutation status for only biomarkers with statistical significance (p < 0.05) in overall analyses. Tree-structured survival What's new? EGFR inhibitors have shown promise for treating non-small-cell lung cancer (NSCLC) in some patients. However, new biomarkers are urgently needed to predict which patients are likely to respond to treatment. In this study of late-stage NSCLC patients with EGFR mutations, the authors found that pretreatment levels of bilirubin and total cholesterol were significantly associated with overall survival, regardless of what therapy was given. Higher circulating bilirubin appeared to be a significant risk factor, while higher cholesterol was associated with improved survival.
analysis was used to distinguish patients with divergent median follow-up time by the recursive-partitioning method (STREE software, available at the website http://c2s2.yale.edu/ software/stree/).
All statistical analyses were completed with the SPSS software version 20.0 for Windows (IBM SPSS Inc., Chicago, IL, USA) unless otherwise indicated. A na€ ıve two-sided p values of 0.05 was set as the significance cutoff point and then 
Abbreviations: NSCLC, non-small-cell lung cancer; TNM stage, tumor-node-metastasis stage; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TB, total bilirubin; DB, direct bilirubin; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; IQR, interquartile range.
subject to the Bonferroni correction to adjust for multiple comparisons.
Results
Patient characteristics
During the period between January 2009 and December 2013, initially 482 consecutive NSCLC patients met our inclusion criteria. Thereof, 43 patients were excluded from the final analysis, and 23 of them had no data on bilirubin and/ or cholesterol. Accordingly, a total of 459 advanced NSCLC patients with positive EGFR mutations were analyzed in this study, and their baseline characteristics are summarized in 
Association of pretreatment bilirubin and cholesterol with OS
The median follow-up time and survival time were 29.5 and 34.9 months, respectively. In multivariate Cox analyses, only pretreatment DB, TC and HDL-C were significantly Fig. 1b) , as compared with patients with lower TC levels (5.06 mmol/L). As for HDL-C, patients with higher levels (>1.29 mmol/L) had longer MST (50.1 vs 37.3 months, Log-rank test p 5 0.029; Fig. 1c ) and had the risk of death reduced by 46% (HR 5 0.54, 95% CI: 0.29-1.00, p 5 0.049) compared with patients with lower levels (1.29 mmol/L). After the Bonferroni correction, significance was retained for DB and TC at a significance level of 1% (0.05/5, here 5 refers to 5 biomarkers under study).
Stratified analyses of significant biomarkers
The association of three significant biomarkers (DB, TC and HDL-C) with OS in NSCLC patients was stratified by gender, smoking status, TNM stage, histology and EGFR mutation status, respectively (Table 3 ). In case of subgroup with sample size <5, effect-size estimates were not presented. Pretreatment DB was significantly associated with OS in never smokers and in patients with stage IV or lung adenocarcinoma. Both elevated TC and HDL-C levels were observed to predict a better prognosis in never smokers, in females, and in patients with stage III, adenocarcinoma or EGFR L858R Abbreviations: NSCLC, non-small-cell lung cancer; EGFR, epidermal growth factor receptor; TB, total bilirubin; DB, direct bilirubin; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HR, hazard ratio; 95% CI, 95% confidence interval. 1 P was adjusted for age, gender, smoking, TNM stage, histology, first-line therapy, ECOG PS score, EGFR mutation status hepatic metastasis, thoracic radiotherapy and neoadjuvant therapy under multivariate Cox proportional hazards model. **In case of subgroup with sample size <5, effect-size estimates were not presented.
mutation. Improved OS was seen for elevated TC in male patients (HR 5 0.33, 95% CI: 0.13-0.84, p 5 0.019).
Survival tree analyses
Tree-structured survival analysis was performed to examine the prognostic utility of aforementioned significant biomarkers in NSCLC patients. The top splitting factor was TC, followed by DB and HDL-C, resulting in a four-terminalnode tree (Fig. 2a) . 
Discussion
To the best of our knowledge, this is so far the first study that has evaluated the association of pretreatment circulating bilirubin and cholesterol with OS in NSCLC patients with EGFR mutations. The key finding of this study was that DB was identified as a significant risk factor, yet TC as a protective factor, for the OS of NSCLC patients with EGFR mutations. Recently, several studies have observed an improvement in the OS of NSCLC patients with EGFR mutations. For instance, a median OS period was reported to be 27.7 months in the NEJ002 study, 6 34.8 months in the WJOG3405 study 24 and 30.8 months in the study by Inoue et al. 25 The median OS in the current study was 34.9 months, which was comparable with that of previous studies. Bilirubin is the final decomposition product of heme catabolism, and it is accepted as an anticancer factor due to the antioxidant function. 16, 26 There is compelling evidence that reduced bilirubin was associated with an increased cancer risk, 15, 27, 28 including lung cancer. 13 They also postulated that the protective nature of bilirubin was attributable to its antioxidation, anti-inflammation and antiprolification properties. Contrastingly in our study, direct bilirubin-accounting for 20% of total bilirubin-was identified as a risk factor for the prognosis of advanced NSCLC patients with EGFR mutations. In support of our findings, a recent experimental study demonstrated that bilirubin could induce lung alveolar epithelial cell death both in vitro and in vivo. 34 There are two possible reasons for this discrepancy.
One possibility may be explained by different patients' characteristics. In the study by Li et al., 30 only early-stage NSCLC patients (stage IA-IIIA) were analyzed, whereas in this study we only enrolled patients at late stages (stage IIIA-IV). The impact of serum bilirubin, if involved, might be divergent between patients with early-and late-stage NSCLC. Another possible reason is that EGFR mutation status may account for the conflicting findings between Li et al.'s study and this study. Although no direct evidence existed to connect bilirubin and EGFR mutations, our findings are biologically plausible and we agree that external validation in another prospective cohort is encouraging. Total cholesterol is the total amount of cholesterol in the blood. Clinical and experimental data have indicated that alternations in cholesterol metabolism may play a key role in carcinogenesis and tumor development. 35 However, lowered TC was reported to be significantly associated with increased lung cancer risk in some 19, 20 but not all 36,37 studies. Originally, the concern about circulating TC was primarily focused on its contribution to the prognosis of coronary heart disease. 38 Recent evidence has suggested a carcinogenic role of circulating TC in lung cancer survival. 39, 40 For instance, Sok et al. observed that lung cancer patients with lower TC had a significant shorter OS period than those with higher TC (5- year survival rate: 41% vs 56%, p < 0.05). 39 Another study by Li et al. found that reduced serum TC was an independent prognostic factor for worse OS in resectable NSCLC patients (HR 5 2.9, 95% CI: 1.01-4.47), 40 in agreement with the findings of this study among advanced NSCLC patients with EGFR mutations. Cholesterol is accumulated in special regions of the membrane, and combined with sphingolipids to create highly stable and small compartmentalized microdomains known as lipid rafts. 35 Lipid rafts are reported as the sites of signaling platforms, which could convey stimuli of the extracellular milieu to the intracellular systems in both normal and cancer cells. 35 EGFR is also associated with lipid rafts, which signaling events are dependent on the cholesterol content of lipid rafts. 41, 42 And the results of a basic research revealed that lipid raft localization of EGFR was correlated with resistance to EGFR TKI and the resistance could be decreased by pharmacological depletion of cholesterol from lipid rafts. 43 Above evidence collectively revealed a potential connection between cholesterol and EGFR signaling, which could partly explain the reason why cholesterol level could serve as a predictor of the prognosis of NSCLC patients with EGFR mutations. In our stratified analysis, the correlation between higher TC and better prognosis of NSCLC patients could only be found in stage III patients. Cancer cachexia may be a potential confounder for stage IV patients, which always result in an abnormal level of cholesterol and partly hides the effect of TC in predicting the OS of stage IV NSCLC patients.
It is well known that HDL-C acts as a supplier of cholesterol to cancer cells by removing excess cholesterol from peripheral tissues. 35 Several studies have reported a significant inverse relation between HDL-C and the risk of cancer at many sites, including lungs. [44] [45] [46] As exemplified in the study by Chi et al., lowered HDL-C before surgery was associated with poor survival in NSCLC patients (HR 5 2.7, 95% CI: 1.69-4.33, p < 0.001). 47 Another study by Lv et al. indicated that elevated HDL-C was an independent predictive factor of EGFR mutations, as well as a protective factor of progression-free survival in lung adenocarcinoma patients with EGFR mutations. 48 As an extension in this study, elevated HDL-C was significantly associated with an improvement in the OS of advanced NSCLC patients with EGFR mutations. However, a note of caution should be sounded as this association was nonsignificant after the Bonferroni correction, likely due to the inadequate statistical power. Nevertheless, a more complete understanding of the biological mechanisms of HDL-C in lung carcinogenesis will be needed to better define the prognosis and likelihood of a therapeutic response in individual patients, especially with NSCLC.
This study is not without its limitations. On one hand, all enrolled patients had positive EGFR mutations, which limited us to further analyze the association between metabolic biomarkers and EGFR mutations. On the other hand, as a specialized hospital, lipid examination was not performed as a routine test in our department. Data on circulating cholesterol were missing from some patients.
In summary, our findings demonstrate for the first time that pretreatment DB was identified as a significant risk factor, yet TC as a protective factor, for the OS of NSCLC patients with EGFR mutations. The exact implications of these two metabolic biomarkers in the prognosis of NSCLC patients will only be elucidated in the future by large, welldesigned cohort patients in which replication can be undertaken, along with in vitro and in vivo functional characterization.
